NasdaqGS:REPLBiotechs
Is Replimune Group (REPL) Fully Valued Following FDA Approval Of TUDRIQEV?
Replimune Group (REPL) drew fresh attention after the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab in advanced cutaneous melanoma, supported by Phase 2 data and followed by commercialization-focused updates.
See our latest analysis for Replimune Group.
The share price reaction around the TUDRIQEV approval has been sharp, with a 30 day share price return of 46.33% and a 90 day share price return of 218.51%. The 1 year total shareholder return of 180.86% sits...